Lineage Cell Therapeutics

Lineage Cell Therapeutics

Yahoo Finance • last month

Hedge Fund Broadwood Capital Added Over 1 Million Shares of STAAR Surgical to Its Position. Here's What That Means for Investors.

What happened According to an SEC filing dated May 14, 2026, Broadwood Capital purchased 1,104,351 shares of STAAR Surgical Company.(NASDAQ:STAA) during the first quarter, an estimated $21.08 million transaction based on the quarter’s ave... Full story

Yahoo Finance • 2 months ago

Lineage targets operations into Q2 2028 as it launches COR1 and scales ILT1 manufacturing

Earnings Call Insights: Lineage Cell Therapeutics (LCTX) Q1 2026 MANAGEMENT VIEW * Brian Culley (CEO, President & Director) highlighted platform expansion and new pipeline launches: "I do definitely want to highlight the successful exp... Full story

Yahoo Finance • 4 months ago

Lineage extends cash runway into Q2 2028 while advancing OpRegen and new pipeline programs

Earnings Call Insights: Lineage Cell Therapeutics (LCTX) Q4 2025 MANAGEMENT VIEW * CEO Brian Culley opened the call highlighting recent warrant exercises that have further extended the company's cash runway and announced a positive res... Full story

Yahoo Finance • 5 months ago

trivago Leads The Pack Of 3 Promising Penny Stocks

As February begins, major U.S. stock indexes have surged, with the Dow Jones Industrial Average climbing by 515 points and the S&P 500 nearing a record high. In such a robust market environment, investors might consider exploring opportuni... Full story

Yahoo Finance • 8 months ago

The Biotech Sector is Seeing a Major Boost From Programmable Cell Therapies in Chronic Disease Care

Issued on behalf of Avant Technologies Inc. VANCOUVER, British Columbia, Nov. 19, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – The autologous cell therapy market surpassed $10.1 billion in 2025 as biotechnology companies ra... Full story

Yahoo Finance • 8 months ago

Lineage extends cash runway into Q2 2027 as OpRegen site expansion accelerates and new partnerships advance pipeline

Earnings Call Insights: Lineage Cell Therapeutics (LCTX) Q3 2025 MANAGEMENT VIEW * CEO Brian Culley opened with an update on OpRegen, highlighting that "Genentech opened 2 new clinical sites last month and 5 new clinical sites were ope... Full story

Yahoo Finance • 10 months ago

Lineage Cell Therapeutics, Inc. (LCTX) Shows Vision Gains in Phase 1/2a OpRegen Trial

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Lineage Cell Therapeutics, Inc. is one of them. Lineage Cell Therapeutics, Inc. (NYSE:LCTX) is a clinical-stage biotech company developi... Full story

Yahoo Finance • 11 months ago

Lineage Cell Revenue Doubles in Q2

Key Points GAAP revenue doubled in Q2 2025 compared to Q2 2024, significantly beating analyst expectations on a GAAP basis as Collaboration income (GAAP) also doubled compared to Q2 2024. Net loss (GAAP) increased sharply due to large non... Full story

Yahoo Finance • 11 months ago

Lineage signals expanded diversification strategy following OpRegen milestones and $42.3M cash position

Earnings Call Insights: Lineage Cell Therapeutics (LCTX) Q2 2025 MANAGEMENT VIEW * CEO Brian M. Culley highlighted sustained progress for OpRegen, noting "the anatomical and functional benefits, which we first reported have lasted for... Full story

Yahoo Finance • 11 months ago

Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Successfully Reduced-to-Practice Critical Aspect of Commercial-Scale, Cell-Based, GMP Production Processes First Chronic P... Full story

Yahoo Finance • last year

OpRegen ® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

Mean vision gains of +9 letters among patients with extensive coverage of OpRegen cell therapy to the Geographic Atrophy (GA) lesion siteEvidence of retinal structural improvement persisted out to 3 yearsAnatomical and functional improveme... Full story

Yahoo Finance • 3 years ago

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2023 Earnings Call Transcript

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2023 Earnings Call Transcript May 11, 2023 Lineage Cell Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.03 EPS, expectations were $-0.02478. Operator: Welcome to the... Full story

Yahoo Finance • 4 years ago

Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer

CARLSBAD, Calif., October 31, 2022--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that... Full story

Yahoo Finance • 4 years ago

Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Advanced RG6501 (OpRegen®) Development in Partnership with Roche and Genentech Published OPC1 Phase 1/2a Clinical Study Results in Journal of Neurosurgery: Spine Completed Key Activities to Support Planned Regulatory Interactions for OPC1... Full story

Yahoo Finance • 4 years ago

Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Reported RG6501 (OpRegen®) Clinical Results at 2022 ARVO Meeting; Outer Retinal Structure Improvement Observed in Five Dry AMD Patients Expanded Pipeline with Two New Cell Therapy Development Programs; Auditory Neurons and Photoreceptors A... Full story

Yahoo Finance • 4 years ago

Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022

Fireside Chat with B. Riley Research Analyst Scheduled for 3:30pm Eastern Time Topics Will Include Two New Cell Therapy Programs Launched Following Roche and Genentech Partnership for RG6501 (OpRegen®) Program CARLSBAD, Calif., April 26,... Full story

Yahoo Finance • 4 years ago

Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer

CARLSBAD, Calif., April 13, 2022--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Ca... Full story